Venous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients

Urbanek, Tomasz; Krasiński, Zbigniew; Kostrubiec, Maciej; Sydor, Wojciech; Wysocki, Piotr J.; Antoniewicz, Artur A.; Begier-Krasińska, Beata; Dyszkiewicz, Wojciech; Kulig, Jan; Ładziński, Piotr; Markowska, Janina; Ramlau, Rodryg; Rutkowski, Piotr; Sajdak, Stefan; Ziaja, Damian; Ziaja, Krzysztof

doi:10.5603/aa.2016.0011

Cited by 3 publications

(5 citation statements)

References 216 publications

(365 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, two guidelines were published in 2011 [ 34 , 35 ], nine in 2012 [ 36 – 44 ] and 16 (59%) [ 5 , 45 – 59 ] were published, updated, or re-affirmed between 2013 and 2017, inclusive. Just under half (k = 13 [ 5 , 36 – 38 , 40 – 44 , 53 , 55 , 56 , 58 ]) were developed by groups located in the United States, and an additional 13 CPGs were developed by groups based exclusively in Europe (k = 8 [ 34 , 35 , 39 , 45 , 50 – 52 , 59 ]) and Canada (k = 5 [ 46 – 49 , 57 ]). Additionally, one CPG [ 54 ] was developed by an international group of experts across Europe (Czech Republic, France, and the United Kingdom) and North America.…”

Section: Resultsmentioning

confidence: 99%

“…Most guidelines (63%) used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group approach (k = 6 [ 34 , 50 – 52 , 57 , 59 ]), or various adaptations of thereof (k = 11 [ 5 , 36 – 38 , 40 – 44 , 49 , 53 ]), to assess the quality of evidence upon which their recommendations were informed. Three CPGs [ 35 , 39 , 57 ] adapted assessment systems used by other groups (e.g.…”

Section: Resultsmentioning

confidence: 99%

“…The remaining three CPGs [ 47 , 48 , 54 ] were assessed scores of greater than 60 percent in only two domains, but scored at least 50 percent in domain three. Eight CPGs [ 34 , 35 , 46 , 50 , 53 , 56 , 57 , 59 ] judged to be of low quality were assessed scores of less than 60 percent in two or more domains and were not assessed a score at least 50 percent in domain three.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making

et al. 2018

View full text Add to dashboard Cite

BackgroundVenous thromboembolism (VTE) is a major global cause of morbidity and mortality. Low molecular weight heparin (LMWH) and fondaparinux (FDP) are frequently used to treat and prevent VTE and have a variety of safety and practical advantages over other anticoagulants, including use in outpatient settings. These medications are commonly listed on drug formularies, which act as a gateway for health plan prescription coverage by outlining the circumstances under which patients will be covered for specific drugs and drug products. Because patient access to medications is impacted by the nature of their listing on formularies, they must be rigorously reviewed and modernized as new evidence emerges.MethodsAs part of a broader drug class review team, we completed a systematic review of clinical practice guidelines to determine whether the recommendations they reported aligned with the indications listed for the coverage of LMWH and FDP in an outpatient drug formulary. Guideline quality was assessed using the Appraisal of Guidelines for Research & Evaluation (AGREE) II tool. Recommendation matrices were used to systematically compare, categorize, and summarize included recommendations.ResultsTwenty-seven guidelines were included from which 168 eligible recommendations were identified. Generally, AGREE II domains were adequately addressed; however, domain five (applicability) was poorly addressed. Most recommendations were based on moderate- to low-quality/limited evidence and reported on the use of LMWHs generally; few reported on specific agents.ConclusionsOur findings contributed to the recommendation that the formulary listing for LMWH and FDP be streamlined to include coverage for specific outpatient indications. The paucity of available evidence on the comparative efficacy of specific LMWH agents against each other and FDP limited agent-specific listing recommendations, highlighting the need for high-quality comparative studies on this topic.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The feasibility of implementing the guidelines was also assessed prior to publication. Each recommendation is annotated with the type and strength of the recommendation and the quality of the evidence assessed using standardized criteria that were also used in previous 2016 guidelines [5].…”

Section: Overview Of the Updating Processmentioning

confidence: 99%

Wytyczne leczenia i profilaktyki żylnej choroby zatorowo-zakrzepowej u chorych onkologicznych leczonych operacyjnie z uwzględnieniem chorych poniżej 18. roku życia

Krasiński¹,

Urbanek²,

Undas³

et al. 2021

Acta Angiologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 Subsequently, further documents certified by the Polish Working Group were published, which were dedicated to particular subgroups of patients, especially oncological ones. 7,8 The documents were also published in other countries. An updated National Institute for Health and Care Excellence (NICE) guidance on VTE, published in March 2018, was aimed at reducing the incidence of hospital -associated VTE.…”

mentioning

confidence: 99%

Mechanical methods of venous thromboembolism prevention – from the guidelines to the clinical practice

Tamowicz

Mikstacki

Urbanek

et al. 2019

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

Mechanical antithrombotic prophylaxis 335 postthrombotic syndrome treatment costs, vastly outweigh the costs of antithrombotic prophylaxis. Based on research studies and observational data, the widely available methods of prophylaxis are highly effective, also in terms of the costs. 3 The majority of hospitalized patients are burdened with at least 1 risk factor for VTE. The risk factors include age of more than 40 years, obesity (body mass index >30 kg/m 2), positive family history of VTE, multiorgan trauma, stroke, paresis or paraplegia, long-term immobilization, cancer, previous VTE, congenital or acquired thrombophilia, sepsis, New York Heart Association (NYHA) functional class III or IV, respiratory failure, autoimmune diseases, nephrotic syndrome, myeloproliferative disease, nocturnal paroxysmal hemoglobinuria, external venous compression (eg, tumor, hematoma, and arterial malformation), pregnancy and puerperium, long-term immobilization associated with travel (eg, long-distance flight), varicose veins in the lower limbs, obesity, and acute infection. 1,3 The risk factors related to diagnostic and therapeutic interventions are surgical procedures (especially major surgery in the lower limbs, pelvis, and abdomen), catheter placement in large veins, anticancer treatment (chemotherapy), hormonal treatment, use of angiogenesis inhibitors, use of oral contraceptives,

show abstract

Venous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients

Cited by 3 publications

References 216 publications

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making

A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making

Wytyczne leczenia i profilaktyki żylnej choroby zatorowo-zakrzepowej u chorych onkologicznych leczonych operacyjnie z uwzględnieniem chorych poniżej 18. roku życia

Mechanical methods of venous thromboembolism prevention – from the guidelines to the clinical practice

Contact Info

Product

Resources

About